Covid: Natco Pharma seeks approval for Molnupiravir capsules phase 3 trials
Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organization (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.
American
pharma major Merck along with Ridgeback Biotherapeutics has developed
Molnupiravir(MK-4482).
According
to a press release from the city-based drug maker, pre-clinical data have shown
that Molnupiravir has broad anti-influenza activity, including highly potent
inhibition of SARS-CoV-2 replication.
"Patients
treated with Molnupiravir achieved response within 5 days of therapy indicating
that the duration of treatment with Molnupiravir is short, with the additional
advantage of being an oral therapy," it said.
Comments
Post a Comment